Clinical trial
A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)
NCT04109924 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)
- Lead sponsor
- Roswell Park Cancer Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 27, 2019
- Completion date
- September 5, 2024
- Enrollment
- 42 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
advanced colorectal carcinoma, metastatic colon adenocarcinoma, metastatic rectal adenocarcinoma, recurrent colon adenocarcinoma, recurrent colorectal adenocarcinoma, recurrent rectal adenocarcinoma, stage iii colon cancer ajcc v8, stage iii colorectal cancer ajcc v8, stage iii rectal cancer ajcc v8, stage iiia colon cancer ajcc v8, stage iiia colorectal cancer ajcc v8, stage iiib colorectal cancer ajcc v8, stage iiib rectal cancer ajcc v8, stage iiic colon cancer ajcc v8, stage iiic colorectal cancer ajcc v8, stage iv colon cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage iva rectal cancer ajcc v8, stage ivb colon cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivb rectal cancer ajcc v8, stage ivc colon cancer ajcc v8, stage ivc colorectal cancer ajcc v8, stage ivc rectal cancer ajcc v8, unresectable colon adenocarcinoma, unresectable colorectal carcinoma, unresectable rectal adenocarcinoma